GLP-1 and menopause: what to know about weight gain, HRT, muscle and bone
GLP-1 medicines work in midlife women, but menopause-specific evidence is thin and mostly observational. In two small retrospective studies, postmenopausal women on hormone therapy lost more weight on semaglutide (16% vs 12% at 12 months) and tirzepatide (17% vs 14%). Experts say that isn't a reason to start HRT for weight. Protect muscle and bone, and plan with your doctor.
Why does weight change around menopause?
Many women notice their shape changing in their late 40s and early 50s. The long-running SWAN study measured this with DXA scans. At the start of the menopause transition, the yearly rate of fat gain roughly doubled, and lean mass started to fall. Both trends continued until about two years after the final period, then leveled off.
The surprising part: weight on the scale didn’t speed up. Instead, more of it shifted from lean mass to fat. Over a transition of about 3.5 years, that came to roughly 6% more fat mass and a small loss of lean mass for the average participant.
That matters for anyone thinking about a GLP-1 at this stage. A later SWAN analysis linked more lean-mass loss during the transition with lower hip bone density and more fractures afterwards. So the goal is not only less weight but keeping muscle and bone.
Do GLP-1 medicines work for menopause weight gain?
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) do lead to weight loss after menopause: in the two observational studies below, women lost roughly 12% to 17% of their weight. What’s missing is strong, menopause-specific evidence. A 2026 position statement from the Spanish Menopause Society concluded that semaglutide has the most direct data so far, and that even this is limited and mostly observational. Tirzepatide looks promising but still needs menopause-focused study.
None of these medicines is approved for menopause symptoms. Prescriptions are based on the usual weight-management or type 2 diabetes criteria.
Does HRT change how well Ozempic or Mounjaro works?
Two small studies from the same research group suggest it might:
- Semaglutide (Menopause, 2024): among 106 postmenopausal women, the 16 using hormone therapy lost about 16% of their weight at 12 months, versus about 12% for the 90 who weren’t.
- Tirzepatide (2025 conference abstract): among 120 matched postmenopausal women, those using hormone therapy lost about 17% at last follow-up, versus about 14% without it.
Both studies looked back at medical records rather than randomizing anyone. Women who choose hormone therapy may differ in ways the researchers couldn’t fully adjust for. Expert reviews agree on the practical point: hormone therapy should be prescribed for its usual reasons, such as moderate to severe hot flashes or preventing bone loss, and not to boost weight loss.
Oral progesterone and tirzepatide
If you still have a uterus and take estrogen, a progestogen is usually part of your hormone therapy to protect the womb lining. Tirzepatide slows stomach emptying, and its labels show lower peak levels of birth control pill hormones after a single dose. A 2026 review found no studies of progestogens used in menopause care. It called an interaction plausible but unproven, most likely around starting and dose increases. Tell your prescriber about every hormone you take, and report unexpected bleeding. Our guide to GLP-1 period changes covers bleeding questions in more detail.
Can you get pregnant in perimenopause on a GLP-1?
Yes. The NHS advises contraception for 2 years after your last period if you’re 40 to 49, and for 1 year if you’re 50 or older. HRT doesn’t work as contraception. Tirzepatide can make the pill less effective for 4 weeks after starting and after each dose increase. Semaglutide labels advise stopping at least 2 months before a planned pregnancy. See our GLP-1 birth control guide for the details.
How do you protect muscle and bone on a GLP-1 after 45?
Midlife already tilts body composition away from muscle, and some of any large weight loss is lean mass. Our guide on preventing muscle loss on a GLP-1 covers strength training and monitoring, and the protein target guide explains how to set your number.
Bone deserves its own conversation:
- Fracture signal: the Wegovy label notes that in its cardiovascular outcomes trial, hip and pelvis fractures were reported in 1% of women on Wegovy versus 0.2% on placebo. That is a small absolute difference from one trial and doesn’t prove the drug caused it.
- Exercise may help: in a Danish trial, a year of liraglutide alone lowered hip and spine bone density compared with exercise. Liraglutide plus exercise kept bone density similar to placebo. Participants were younger (average age about 43), so results may not carry over to postmenopausal women.
- Everyday habits: the NHS recommends weight-bearing exercise and strength work around menopause to help protect bones.
Ask your doctor whether your history calls for a bone density scan or other tests. Our guide to GLP-1 doctor visits and lab tests can help you prepare.
What should you discuss with your clinician?
Before starting
- Your menopause stage and symptoms, and whether you use or are considering hormone therapy
- Every hormone you take, especially oral progesterone or other progestogens
- Contraception, if you’ve had a period in the last 1 to 2 years
- Fracture risk: past fractures, family history, steroid use, prior bone scans
During treatment
- How you’ll track muscle and strength, not only weight
- What bleeding pattern to expect on your hormone therapy, and what to report
- When to recheck labs and, if needed, bone density
When should you call your doctor?
- Any bleeding 12 months or more after your last period, even spotting. The NHS says this should always be checked. A 2026 case report described bleeding after starting semaglutide, but one case can’t show a link, and other causes come first.
- Irregular, heavier or spotting bleeding that continues after 6 months on HRT
- Periods much heavier than usual during perimenopause
- A positive pregnancy test
- Severe stomach pain that won’t go away, or vomiting that stops you keeping fluids down
- A fall with hip, back or wrist pain
- Swelling of the face or throat or trouble breathing (call emergency services)
The bottom line
GLP-1 medicines can help with midlife weight, and early data hint that hormone therapy users may lose a little more. That evidence is too weak to guide treatment by itself. What matters is protecting muscle and bone, keeping contraception right in perimenopause, and reporting unexpected bleeding. GLPMate’s weight tracker keeps your trend and body measurements together, and the daily Journal is a simple place to note hot flashes, sleep or bleeding next to your doses.
This article is educational only and not medical advice. Talk to your doctor or menopause specialist about what fits your health history.
FAQ
Does Ozempic or Mounjaro work for menopause weight gain?
GLP-1 medicines can lead to weight loss after menopause, but few studies look specifically at menopausal women, and most are observational. A Spanish Menopause Society statement notes semaglutide has the most menopause-specific data so far, while tirzepatide still needs menopause-focused study. Your doctor can tell you whether you meet the criteria for a weight-management or diabetes prescription.
Should I start HRT to lose more weight on a GLP-1?
No. Two small retrospective studies found postmenopausal women already using hormone therapy lost more weight on semaglutide or tirzepatide, but they can't prove the hormones caused it. Expert reviews say HRT should be prescribed for its usual reasons, such as hot flashes or bone protection, and not to boost weight loss.
Can I take Mounjaro or Ozempic with HRT?
Often, yes; the US labels don't specifically mention menopausal hormone therapy among drug interactions. Tirzepatide slows stomach emptying, and a 2026 review called an effect on oral progestogens, such as progesterone taken to protect the uterus, plausible but unproven. Tell your prescriber about every hormone you take and report any unexpected bleeding.
Does a GLP-1 cause bone loss after menopause?
It isn't settled. In the Wegovy cardiovascular trial, hip and pelvis fractures in women were reported in 1% on Wegovy versus 0.2% on placebo, and a liraglutide study found lower bone density without exercise. Ask your doctor about your fracture risk, and keep up strength training, protein and weight-bearing activity.
Sources
- Greendale et al., JCI Insight 2019 — changes in body composition and weight during the menopause transition (SWAN, DXA) — fat gain rose from about 1.0% to 1.7% a year and lean mass started to fall at the start of the transition, until about 2 years after the final period; weight gain itself did not accelerate
- Shieh et al., J Bone Miner Res 2023 — menopause-related body composition changes, bone density and fractures (SWAN) — more lean mass loss during the transition was linked to lower hip bone density and more fractures afterwards
- Hurtado et al., Menopause 2024 — semaglutide in postmenopausal women with and without hormone therapy (retrospective cohort) — 16 women on HT vs 90 not; 12-month weight loss 16% vs 12%; authors call for larger studies
- Bechenati et al., J Endocr Soc 2025 (ENDO 2025 abstract SAT-688) — tirzepatide in postmenopausal women with and without hormone therapy — 120 propensity-matched women; weight loss 17% vs 14% at last follow-up (median about 18 months); conference abstract, not peer-reviewed in full
- Sánchez-Prieto et al., Maturitas 2026 — Spanish Menopause Society position statement on incretin-based therapies in peri- and postmenopausal women — menopause-specific evidence limited and largely observational; HT link with greater weight loss is hypothesis-generating and not a reason to start HT for weight; emphasis on muscle, fracture risk, resistance exercise and protein
- Younglove, Obesity Pillars 2026 — clinical review: menopause hormone therapy in weight management — MHT is prescribed for established indications such as moderate to severe hot flashes and osteoporosis prevention, not for weight loss
- Viana et al., Maturitas 2026 — tirzepatide and oral progestogens, hypothesis-generating review — no pharmacokinetic data for progestogens used in menopausal hormone therapy; an interaction is plausible but unproven, most likely during initiation and dose increases
- Wegovy (semaglutide) US Prescribing Information — DailyMed, revised 06/2026 — in the cardiovascular outcomes trial, hip and pelvis fractures in female patients 1% (24/2,448) vs 0.2% (5/2,424) on placebo
- Jensen et al., JAMA Network Open 2024 — bone health after exercise, liraglutide or both (secondary analysis of an RCT) — liraglutide alone lowered hip and spine bone density vs exercise; liraglutide plus exercise kept bone density similar to placebo
- NHS — Menopause and perimenopause symptoms (accessed October 2026) — contraception for 2 years after the last period if aged 40–49 and 1 year if 50 or over; see a GP for any bleeding after 12 months without a period, or for irregular bleeding after 6 months on HRT
Sources checked:
This article is educational and is not medical advice, diagnosis or treatment. Medication decisions — including dose changes and what to do after a missed dose — belong with your prescriber. If you experience severe symptoms, seek medical care.